These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36108289)

  • 1. Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action.
    Cooper W; Ray S; Aurora SK; Shrewsbury SB; Fuller C; Davies G; Hoekman J
    J Aerosol Med Pulm Drug Deliv; 2022 Dec; 35(6):321-332. PubMed ID: 36108289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD
    Smith TR; Winner P; Aurora SK; Jeleva M; Hocevar-Trnka J; Shrewsbury SB
    Headache; 2021 Sep; 61(8):1214-1226. PubMed ID: 34363701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD
    Shrewsbury SB; Jeleva M; Satterly KH; Lickliter J; Hoekman J
    Headache; 2019 Mar; 59(3):394-409. PubMed ID: 30659611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal Delivery of Acute Medications for Migraine: The Upper Versus Lower Nasal Space.
    Martin V; Hoekman J; Aurora SK; Shrewsbury SB
    J Clin Med; 2021 Jun; 10(11):. PubMed ID: 34199479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
    Silberstein S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1961-8. PubMed ID: 22860628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
    J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breath powered nasal delivery: a new route to rapid headache relief.
    Djupesland PG; Messina JC; Mahmoud RA
    Headache; 2013 Sep; 53 Suppl 2():72-84. PubMed ID: 24024605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydroergotamine nasal spray in the treatment of acute migraine.
    Treves TA; Kuritzky A; Hering R; Korczyn AD
    Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.
    Silberstein SD; Kori SH
    CNS Drugs; 2013 May; 27(5):385-94. PubMed ID: 23620146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group.
    Gallagher RM
    Arch Neurol; 1996 Dec; 53(12):1285-91. PubMed ID: 8970458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
    Silberstein SD; Shrewsbury SB; Hoekman J
    Headache; 2020 Jan; 60(1):40-57. PubMed ID: 31737909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroergotamine nasal spray for the acute treatment of migraine.
    Ziegler D; Ford R; Kriegler J; Gallagher RM; Peroutka S; Hammerstad J; Saper J; Hoffert M; Vogel B; Holtz N
    Neurology; 1994 Mar; 44(3 Pt 1):447-53. PubMed ID: 8145914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine.
    Cady R
    Expert Opin Drug Deliv; 2015; 12(9):1565-77. PubMed ID: 26119828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human pharmacokinetics of dihydroergotamine administered by nasal spray.
    Humbert H; Cabiac MD; Dubray C; Lavène D
    Clin Pharmacol Ther; 1996 Sep; 60(3):265-75. PubMed ID: 8841149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
    Goldstein J
    Neurology; 1992 Mar; 42(3 Suppl 2):45-6. PubMed ID: 1557192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.